Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTI-004 phase 3 trial of eftilagimod alfa added to pembrolizumab and chemotherapy in advanced/metastatic NSCLC
2024-513621-23-00Phase 3Completed
- Sponsor
- Immutep Limited
- Start
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Eftilagimod alfa + pembrolizumab + chemotherapy with Placebo + pembrolizumab + chemotherapy (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started Mar 2025; status: completed.
02
Drugs
eftilagimod alpha
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-513621-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513621-23-00.